• Contact us
  • Customer support
  • Login
  • Home
  • Technology
    • Introduction
    • The Process
    • Clinical
    • Protocols
    • Get Started
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • Steen Solution™
    • Perfadex®
    • Perfadex® Plus
    • Silicone Tubing Set™
    • XVIVO LS™ & XVIVO Disposable Lung Set™
    • Organ Chamber™
    • Lung Cannula Set™
  • Knowledge
    • NOVEL study
    • Literature
    • Movies
  • Media
    • Videos
    • Insights
  • About us
    • About Xvivo
    • History
    • Training and workshops
    • Our market
    • News
    • Career
  • Corporate
    • Corporate
    • The share
    • Press releases
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports and prospectus
      • Interim reports
      • Annual reports
      • Prospectus
    • Financial presentations
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
    • Analyst Coverage
    • CODE OF CONDUCT
    • Privacy policy
    • Subscribe
    • Unsubscribe
    • Thank you
    • Error
XVIVO Perfusion
  • Contact us
  • Customer support
  • Login
  • Home
  • Technology
    • Introduction
    • The Process
    • Clinical
    • Protocols
    • Get Started
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • Steen Solution™
    • Perfadex®
    • Perfadex® Plus
    • Silicone Tubing Set™
    • XVIVO LS™ & XVIVO Disposable Lung Set™
    • Organ Chamber™
    • Lung Cannula Set™
  • Knowledge
    • NOVEL study
    • Literature
    • Movies
  • Media
    • Videos
    • Insights
  • About us
    • About Xvivo
    • History
    • Training and workshops
    • Our market
    • News
    • Career
  • Corporate
    • Corporate
    • The share
    • Press releases
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports and prospectus
      • Interim reports
      • Annual reports
      • Prospectus
    • Financial presentations
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
    • Analyst Coverage
    • CODE OF CONDUCT
    • Privacy policy
    • Subscribe
    • Unsubscribe
    • Thank you
    • Error
  • Corporate
  • The share
  • Press releases
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
  • Financial calendar
  • Financial reports and prospectus
    • Interim reports
    • Annual reports
    • Prospectus
  • Financial presentations
  • Corporate governance
    • Article of Association
    • General meetings
    • Board of Directors
    • Senior Management
    • Auditors
    • Board Committees
    • Board and Senior Management share holdings
    • Guidelines for remuneration
    • Nomination Committee
  • Analyst Coverage
  • CODE OF CONDUCT
  • Privacy policy
  • Subscribe
  • Unsubscribe
  • Thank you
  • Error

Annual report 2012

Today XVIVO Perfusion is publishing the Annual Report for 2012 (in Swedish). The Annual Report is attached to this press release and will also be available on www.xvivoperfusion.com.

A printed version of the Annual report 2012 can be ordered by phone +46 (0)31 788 21 50 or by email info@xvivoperfusion.com.

April 15, 2013
Gothenburg
XVIVO Perfusion AB (publ)

For further information please contact: Christoffer Rosenblad, CFO, +46 31 788 21 59, christoffer.rosenblad@xvivoperfusion.com For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com Xvivo Perfusion is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on April 15, 2013 at 2:00 p.m. This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.


XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The Xvivo share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se. XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424. Tel: 46 31 788 21 50. Fax: 46 31 788 21 69. E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com


Press release in PDF format


Xvivo Perfusion AB (publ), Box 53015, SE-400 14 Göteborg.
Org. Nr. 556561-0424.
Tel: 031-788 21 50.
Fax: 031-788 21 69.
E-mail: info@xvivoperfusion.com.
Hemsida: www.xvivoperfusion.com

Denna information skickades av Cision http://www.cisionwire.se
http://news.cision.com/xvivo-perfusion/r/annual-report-2012,c9400326

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The Xvivo share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se. XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424. Tel: 46 31 788 21 50. Fax: 46 31 788 21 69. E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com

About us

XVIVO Perfusion is a medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation.

Contact

Swedish Office
XVIVO Perfusion AB
Box 53015
SE-400 14 Göteborg
Sweden

Phone: +46 31 788 21 50
Fax: +46 31 788 21 69
info@xvivoperfusion.com

Newsletter

I have read and accepted XVIVO Perfusion's Privacy Policy

*By signing up to our newsletter you consent to XVIVO Perfusion sending you our insights newsletter and occasional additional communications. Your personal data will be transfered to a third party newsletter distributor engaged by XVIVO Perfusion. All processing of your personal data is in compliance with the XVIVO Perfusion Privacy Policy. For more information on how we use your personal data, please read XVIVO Perfusion’s Privacy policy

  • Home
  • Technology
  • Products
  • Knowledge
  • Media
  • About us
  • Corporate

Copyright © 2019 XVIVO Perfusion. All rights reserved.

Design mkmedia
To top

We use cookies to improve the user experience on XVIVO Perfusion. Read more about Cookies

Approve